Clearside Biomedical Announces Second Quarter 2024 Financial Results and Provides Corporate Update
12 août 2024 16h05 HE
|
Clearside Biomedical, Inc.
- Phase 2b ODYSSEY Trial in Wet AMD Remains on Track with Topline Data Expected in Late Q3 2024 - - ODYSSEY Safety Review Committee Recommends Trial Continue as Planned with no Serious Adverse...
Clearside Biomedical to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
08 août 2024 07h05 HE
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the...
Emerging Gene Therapies Signal Transformative Shift in Retinal Disorder Treatment, According to Spherix Global Insights
24 juil. 2024 09h56 HE
|
Spherix Global Insights
EXTON, PA., June 20, 2024, July 24, 2024 (GLOBE NEWSWIRE) -- The American Society of Retinal Specialists (ASRS) annual meeting held last week in Stockholm, Sweden, showcased groundbreaking...
Clearside Biomedical to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
02 avr. 2024 07h05 HE
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., April 02, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through...
Beacon Therapeutics launches with £96 million ($120 million) to develop a new generation of gene therapies for retinal diseases resulting in blindness
12 juin 2023 02h00 HE
|
Beacon Therapeutics
PRESS RELEASE Beacon Therapeutics launches with £96 million ($120 million) to develop a new generation of gene therapies for retinal diseases resulting in blindness New leading gene therapy company...
Inherited Retinal Diseases Market to Perceive Highest CAGR of 7.9 by 2029, Size, Share, Trends, Key Drivers, Growth, Challenges and Opportunity Forecast
23 mai 2023 00h30 HE
|
Data Bridge Market Research
OAKLAND, May 23, 2023 (GLOBE NEWSWIRE) -- Data Bridge Market Research's latest report, "Inherited Retinal Diseases Market" provides a thorough analysis of growth strategies, drivers, opportunities,...
Clearside Biomedical Announces First Quarter 2023 Financial Results and Provides Corporate Update
11 mai 2023 07h05 HE
|
Clearside Biomedical, Inc.
- Phase 2b ODYSSEY Trial of CLS-AX in Wet AMD Expected to Open Enrollment in Q2 2023 - - Positive Safety Data, Duration and Biologic Effect of CLS-AX Over 6 Months in OASIS Phase 1/2a Extension...
Surrozen Provides First Quarter 2023 Financial Results and Corporate and Pipeline Updates
10 mai 2023 16h05 HE
|
Surrozen, Inc.
Enrollment ongoing in SZN-043 Phase 1a clinical trial in people with chronic liver disease and in healthy volunteers with safety data expected by the end of 2023 Enrollment ongoing in SZN-1326 Phase...
Lighthouse Guild and Bionic Sight Announce Partnership to Expand Treatment Options for People Who Are Blind
29 nov. 2022 09h00 HE
|
Lighthouse Guild
New York, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Lighthouse Guild, the leading not-for-profit vision and healthcare organization, and Bionic Sight, the developer of treatments and technologies for...
Clearside Biomedical Announces Third Quarter 2022 Financial Results and Provides Corporate Update
09 nov. 2022 07h15 HE
|
Clearside Biomedical, Inc.
- Favorable Safety Results, Durability and Biologic Effect Observed in Cohorts 3 and 4 of CLS-AX OASIS Phase 1/2a Trial - - Recent Positive Data Presentations Highlight the Potential...